PDSB logo

PDS Biotechnology (PDSB) Company Overview

Profile

Full Name:

PDS Biotechnology Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

September 30, 2015

Indexes:

Not included

Description:

PDS Biotechnology is a biopharmaceutical company focused on developing innovative cancer therapies. They use their proprietary technology to create personalized treatments that stimulate the immune system to fight tumors. Their goal is to improve patient outcomes and provide new options for cancer care.

Events Calendar

Earnings

Next earnings date:

Mar 27, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Mar 18, 2019

Analyst ratings

Recent major analysts updates

Feb 24, 25 HC Wainwright & Co.
Buy
Dec 18, 24 HC Wainwright & Co.
Buy
Nov 25, 24 B. Riley Securities
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Oct 24, 24 HC Wainwright & Co.
Buy
Oct 2, 24 HC Wainwright & Co.
Buy
Sep 17, 24 HC Wainwright & Co.
Buy
Aug 20, 24 Alliance Global Partners
Buy
Aug 1, 24 HC Wainwright & Co.
Buy
Jun 12, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for PDS Biotechnology?
  • Does PDS Biotechnology pay dividends?
  • What sector is PDS Biotechnology in?
  • What industry is PDS Biotechnology in?
  • What country is PDS Biotechnology based in?
  • When did PDS Biotechnology go public?
  • Is PDS Biotechnology in the S&P 500?
  • Is PDS Biotechnology in the NASDAQ 100?
  • Is PDS Biotechnology in the Dow Jones?
  • When was PDS Biotechnology's last earnings report?
  • When does PDS Biotechnology report earnings?
  • Should I buy PDS Biotechnology stock now?

What is the ticker symbol for PDS Biotechnology?

The ticker symbol for PDS Biotechnology is NASDAQ:PDSB

Does PDS Biotechnology pay dividends?

No, PDS Biotechnology does not pay dividends

What sector is PDS Biotechnology in?

PDS Biotechnology is in the Healthcare sector

What industry is PDS Biotechnology in?

PDS Biotechnology is in the Biotechnology industry

What country is PDS Biotechnology based in?

PDS Biotechnology is headquartered in United States

When did PDS Biotechnology go public?

PDS Biotechnology's initial public offering (IPO) was on September 30, 2015

Is PDS Biotechnology in the S&P 500?

No, PDS Biotechnology is not included in the S&P 500 index

Is PDS Biotechnology in the NASDAQ 100?

No, PDS Biotechnology is not included in the NASDAQ 100 index

Is PDS Biotechnology in the Dow Jones?

No, PDS Biotechnology is not included in the Dow Jones index

When was PDS Biotechnology's last earnings report?

PDS Biotechnology's most recent earnings report was on Nov 14, 2024

When does PDS Biotechnology report earnings?

The next expected earnings date for PDS Biotechnology is Mar 27, 2025

Should I buy PDS Biotechnology stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions